EMA OKs Seven New Drugs Including First RSV Vaccine For Older Adults

GSK’s Arexvy vaccine for preventing lower respiratory tract disease caused by respiratory syncytial virus in adults aged 60 years and older is among the latest products that the European Medicines Agency said should be approved for use in the EU.

RSV virus
The first respiratory syncytial virus vaccine for older adults could be approved in the EU soon • Source: Shutterstock

Arexvy (recombinant, adjuvanted), from GSK, has moved closer to becoming the first vaccine authorized to help protect older adults from respiratory syncytial virus (RSV) disease, after the European Medicines Agency recommended that the product be approved for marketing across the EU.

The vaccine, for preventing lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 years and older, was...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography